Feletti F, De Bernardi di Valserra M, Contos S, Mattaboni P, Germogli R
Second Institute of Pharmacology, University of Pavia, Italy.
Arzneimittelforschung. 1992 Nov;42(11):1363-7.
Fifty-two-week oral toxicity of a new glucan (Glucanil, Gluimmun) extracted from Candida albicans ATCC 20955 was investigated in rats. The glucan was orally administered in dose levels up to 200 mg/kg/d and was well tolerated. No deviation from normality was observed in mortality, physical appearance and general behaviour of the treated animals. Food and water consumption and body weight gain of glucan-fed groups did not differ from those of control animals. In these groups no alteration of the weight of the main organs was also observed. Hematology, blood chemistry, urinalysis and autopsy findings were within normal ranges in every group of rats treated. No sex difference was noted. In the 200 mg/kg group soft stools or diarrhoea and cecal enlargement with variable hyperplasia of the colon mucosa were observed. These symptoms are typical of exposure to substances which are absorbed incompletely in the small intestine and subjected to microbial metabolism in the cecum and colon. Diarrhoea, cecal enlargement and mucosal hyperplasia are reversible. The no-effect dose level was estimated to be 100 mg/kg/d under these conditions.
对从白色念珠菌ATCC 20955中提取的一种新型葡聚糖（葡聚糖制剂，Gluimmun）进行了大鼠为期52周的口服毒性研究。该葡聚糖以高达200毫克/千克/天的剂量水平口服给药，且耐受性良好。在接受治疗的动物的死亡率、外观和一般行为方面未观察到与正常情况的偏差。喂食葡聚糖的各组动物的食物和水消耗量以及体重增加与对照动物无异。在这些组中，主要器官的重量也未观察到改变。接受治疗的每组大鼠的血液学、血液化学、尿液分析和尸检结果均在正常范围内。未发现性别差异。在200毫克/千克组中，观察到软便或腹泻以及盲肠肿大，伴有结肠黏膜不同程度的增生。这些症状是接触在小肠中吸收不完全、在盲肠和结肠中进行微生物代谢的物质的典型表现。腹泻、盲肠肿大和黏膜增生是可逆的。在这些条件下，无作用剂量水平估计为100毫克/千克/天。
